Cargando…
A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database
Background: A high pre-treatment De Ritis ratio, the aspartate transaminase/alanine aminotransferase ratio, has been suggested to be of prognostic value for mortality in muscle-invasive bladder cancer (MIBC). Our purpose was to evaluate if a high ratio was associated with mortality and downstaging....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699152/ https://www.ncbi.nlm.nih.gov/pubmed/36579483 http://dx.doi.org/10.3390/jpm12111769 |
_version_ | 1784839001330417664 |
---|---|
author | Eriksson, Victoria Holmkvist, Oscar Huge, Ylva Johansson, Markus Alamdari, Farhood Svensson, Johan Aljabery, Firas Sherif, Amir |
author_facet | Eriksson, Victoria Holmkvist, Oscar Huge, Ylva Johansson, Markus Alamdari, Farhood Svensson, Johan Aljabery, Firas Sherif, Amir |
author_sort | Eriksson, Victoria |
collection | PubMed |
description | Background: A high pre-treatment De Ritis ratio, the aspartate transaminase/alanine aminotransferase ratio, has been suggested to be of prognostic value for mortality in muscle-invasive bladder cancer (MIBC). Our purpose was to evaluate if a high ratio was associated with mortality and downstaging. Methods: A total of 347 Swedish patients with clinically staged T2-T4aN0M0, with administered neoadjuvant chemotherapy (NAC) or eligible for NAC and undergoing radical cystectomy (RC) 2009–2021, were retrospectively evaluated with a low ratio < 1.3 vs. high ratio > 1.3, by Log Rank test, Cox regression and Mann–Whitney U-test (MWU), SPSS 27. Results: Patients with a high ratio had a decrease of up to 3 years in disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) (p = 0.009, p = 0.004 and p = 0.009) and 5 years in CSS and OS (p = 0.019 and p = 0.046). A high ratio was associated with increased risk of mortality, highest in DFS (HR, 1.909; 95% CI, 1.265–2.880; p = 0.002). No significant relationship between downstaging and a high ratio existed (p = 0.564 MWU). Conclusion: A high pre-treatment De Ritis ratio is on a population level, associated with increased mortality post-RC in endpoints DFS, CSS and OS. Associations decrease over time and require further investigations to determine how strong the associations are as meaningful prognostic markers for long-term mortality in MIBC. The ratio is not suitable for downstaging-prediction. |
format | Online Article Text |
id | pubmed-9699152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96991522022-11-26 A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database Eriksson, Victoria Holmkvist, Oscar Huge, Ylva Johansson, Markus Alamdari, Farhood Svensson, Johan Aljabery, Firas Sherif, Amir J Pers Med Article Background: A high pre-treatment De Ritis ratio, the aspartate transaminase/alanine aminotransferase ratio, has been suggested to be of prognostic value for mortality in muscle-invasive bladder cancer (MIBC). Our purpose was to evaluate if a high ratio was associated with mortality and downstaging. Methods: A total of 347 Swedish patients with clinically staged T2-T4aN0M0, with administered neoadjuvant chemotherapy (NAC) or eligible for NAC and undergoing radical cystectomy (RC) 2009–2021, were retrospectively evaluated with a low ratio < 1.3 vs. high ratio > 1.3, by Log Rank test, Cox regression and Mann–Whitney U-test (MWU), SPSS 27. Results: Patients with a high ratio had a decrease of up to 3 years in disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS) (p = 0.009, p = 0.004 and p = 0.009) and 5 years in CSS and OS (p = 0.019 and p = 0.046). A high ratio was associated with increased risk of mortality, highest in DFS (HR, 1.909; 95% CI, 1.265–2.880; p = 0.002). No significant relationship between downstaging and a high ratio existed (p = 0.564 MWU). Conclusion: A high pre-treatment De Ritis ratio is on a population level, associated with increased mortality post-RC in endpoints DFS, CSS and OS. Associations decrease over time and require further investigations to determine how strong the associations are as meaningful prognostic markers for long-term mortality in MIBC. The ratio is not suitable for downstaging-prediction. MDPI 2022-10-27 /pmc/articles/PMC9699152/ /pubmed/36579483 http://dx.doi.org/10.3390/jpm12111769 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eriksson, Victoria Holmkvist, Oscar Huge, Ylva Johansson, Markus Alamdari, Farhood Svensson, Johan Aljabery, Firas Sherif, Amir A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database |
title | A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database |
title_full | A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database |
title_fullStr | A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database |
title_full_unstemmed | A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database |
title_short | A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients—A Study of a Clinical Multicentre Database |
title_sort | retrospective analysis of the de ritis ratio in muscle invasive bladder cancer, with focus on tumor response and long-term survival in patients receiving neoadjuvant chemotherapy and in chemo naïve cystectomy patients—a study of a clinical multicentre database |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699152/ https://www.ncbi.nlm.nih.gov/pubmed/36579483 http://dx.doi.org/10.3390/jpm12111769 |
work_keys_str_mv | AT erikssonvictoria aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT holmkvistoscar aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT hugeylva aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT johanssonmarkus aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT alamdarifarhood aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT svenssonjohan aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT aljaberyfiras aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT sherifamir aretrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT erikssonvictoria retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT holmkvistoscar retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT hugeylva retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT johanssonmarkus retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT alamdarifarhood retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT svenssonjohan retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT aljaberyfiras retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase AT sherifamir retrospectiveanalysisofthederitisratioinmuscleinvasivebladdercancerwithfocusontumorresponseandlongtermsurvivalinpatientsreceivingneoadjuvantchemotherapyandinchemonaivecystectomypatientsastudyofaclinicalmulticentredatabase |